Effect of technetium-99 conjugated with methylene diphosphonate on IgM-RF, IgG-RF and IgA-RF

Abstract

To explore the effect of technetium-99 conjugated with methylene diphosphonate (⁹⁹Tc-MDP) on IgM-RF, IgG-RF and IgA-RF (RFs) 47 cases were selected for study, including 33 patients with rheumatoid arthritis (RA) and 15 patients with joint pain/arthritis. After⁹⁹Tc-MDP for drips model being given to the patients by intravenous drip 0.2 g daily for 5 days, the injection A and B models of⁹⁹Tc-MDP were used to the patients by intravenous injection one set daily for 10 days, that was one course of treatment. The next course started after 10 days. Each case used it from 2 to 4 courses of treatment. The RFs in serum were determined by the method of enzymelinked immunoabsorption assay (ELISA) before and after 2 and 4 courses of treatment. In the patients with RA, the concentrations of IgM-RF were 296.2±108.4, IU/ml, 189.5±92.3 IU/ml and 107.8±72.5 IU/ml; the concentrations of IgG-RF were 325.6±126.2 IU/ml, 209.7±98.2 IU/ml and 160.2±80.8 IU/ml; the concentrations of IgA-RF were 330.4±136.3 IU/ml, 210.7±89.2 IU/ml and 148.8±72.2 IU/ml before and after 2 and 4 courses of treatment, respectively. The concentrations of the above RFs were significantly lower after 2 and 4 courses than those before treatment (P<0.05 andP<0.01). There was no significant difference in RFs concentrations in the patients with joint pain/arthritis before and after use of⁹⁹Tc-MDP. In the patients with positive RFs before treatment, the RFs concentrations were decreased significantly after 2 and 4 courses of treatment (P<0.05 andP<0.01). There was no obvious change of RFs concentrations in the patients with negative RFs after treatment of⁹⁹Tc-MDP. It was concluded that⁹⁹Tc-MDP could obviously reduce the abnormally high concentrations of RFs, but not influence the normal RFs, which indicated that⁹⁹Tc-MDP has an important effect on controlling the activities of RA.

Keywords

technetium-99 conjugated with methylene diphosphonate / IgM-RF / IgG-RF / IgA-RF

References

[1] SchaardenkurgD V, et al.. Outcome of rheumatoid factor at diagnosis. J Rheumatol, 1993, 20: 45-45

[2] VaughanJ H. Pathogenic concepts and origins of rheumatoid factor in rheumatoid arthritis. Arthritis Rheum, 1993, 36: 1-1

[3] MaximP. Review criteria for assessment of rheumatoid factor [RF] in vitro diagnostic devices using enzymelinked immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], particle agglutination tests, and laser and rate nephelometry. Immunology Branch, 1997, 21: 11-11